This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Biotech Stock Roundup: Updates From HZNP & CLVS, BioNTech to Acquire Neon
by Zacks Equity Research
A low-key week for the biotech sector with a few pipeline and regulatory updates.
3 Small Drug Stocks Poised to Beat Q1 Earnings Estimates
by Zacks Equity Research
So far this earnings season, the going seems to be good for the medical sector. Let us take a glance at a few small drug companies, which are likely to beat on Q1 earnings.
Alibaba (BABA) Gears Up for Q4 Earnings: What's in Store?
by Zacks Equity Research
Alibaba's (BABA) fourth-quarter fiscal 2019 results are likely to be driven by strength in core e-commerce business. However, trade tensions and competition remain concerns.
Factors Likely to Decide JD.com's (JD) Fate in Q1 Earnings
by Zacks Equity Research
Strength in e-commerce business and international expansion are likely to drive JD.com's first-quarter earnings. However, sluggishness in the third party logistics services unit remains a concern.
Will Life Sciences Sales Boost Bio-Rad's (BIO) Q1 Earnings?
by Zacks Equity Research
Within the Life Sciences segment, high investment in several geographies along with product launches and new technologies is resulting in a strong upside for Bio-Rad (BIO).
What's in Store for Booking Holdings' (BKNG) Q1 Earnings?
by Zacks Equity Research
Booking Holdings' (BKNG) Q1 earnings are likely to reflect strength in all platforms.
What's in the Offing for TripAdvisor's (TRIP) Q1 Earnings?
by Zacks Equity Research
TripAdvisor's (TRIP) first-quarter results are likely to benefit from strong product portfolio and strength in non-hotel business.
Can Epidolex Drive GW Pharmaceuticals' (GWPH) Q2 Earnings?
by Zacks Equity Research
Following the U.S.-commercial launch of Epidolex last November, GW Pharmaceuticals (GWPH) continues to see an uptick from the same.
IPOs and Foreign Investment Propel Biotech: 4 Top Picks
by Nitish Marwah
A steady influx of foreign as well as domestic investments in U.S. biotech has gone a long way in boosting gains for the space.